Mifepristone may halt growth of intracranial tumor that causes hearing loss

April 3, 2018, Massachusetts Eye and Ear Infirmary
Vestibular schwannoma cells treated with mifepristone. Credit: Massachusetts Eye and Ear

Massachusetts Eye and Ear researchers have shown that mifepristone, a drug currently FDA-approved for chemical abortion, prevents the growth of vestibular schwannoma (also known as acoustic neuroma) cells. This sometimes-lethal intracranial tumor typically causes hearing loss and tinnitus. The findings, published online today in Scientific Reports, suggest that mifepristone is a promising drug candidate to be repositioned for the treatment of these tumors.

"Currently, there are no FDA-approved drugs for vestibular schwannomas or the associated hearing loss," said Konstantina Stankovic, M.D., Ph.D., an ear and skull base surgeon and auditory neuroscientist at Mass. Eye and Ear and Harvard Medical School who led the study. "Therefore, there is an unmet medical need to discover drugs with minimal adverse effects that would treat this and reduce or obviate the need for surgery and radiation."

Although histologically non-malignant, vestibular schwannomas are dangerous due to their location. Arising from the Schwann cells of the vestibular (balance) nerve, these tumors can grow to the point of damaging nearby structures—and can lead to death by compressing the brainstem. By compressing nerves in the internal auditory canal, the tumors can cause dizziness and facial nerve paralysis, in addition to hearing loss.

Though vestibular schwannomas affecting both sides are the hallmark of neurofibromatosis type 2 (NF2), a genetic disorder causing tumors to grow at multiple sites throughout a person's life, vestibular schwannomas may also occur sporadically, and on one side only.

Currently, patients with symptomatic or growing vestibular schwannomas can undergo surgical resection (through craniotomy) or radiation therapy; however, both of these procedures come with significant risks.

Vestibular schwannoma cells from an untreated tumor. Credit: Massachusetts Eye and Ear

In the Scientific Reports study, researchers first performed the largest meta-analysis of the vestibular schwannoma transcriptome by studying 80 tumors from patients with sporadic and NF2-associated vestibular schwannomas. Then, through a survey of more than 1,100 candidates (all FDA-approved), they identified a short list of drugs likely to convert the abnormal transcriptional signature of a tumor to a more normal one. They then tested eight of the most promising candidate drugs against cells grown from other human vestibular schwannomas. Their experiments showed that one drug in particular, mifepristone, was most effective. Treatment of vestibular schwannoma cells with mifepristone reduced their proliferation rate by 80 percent.

"Our investigation represents the first application of algorithm-based repositioning of FDA-approved drugs for this tumor class," said first author Jessica Sagers, a PhD student at Harvard Medical School.

Konstantina Stankovic, M.D., Ph.D., ear and skull base surgeon and auditory neuroscientist at Mass. Eye and Ear. Credit: John Earle for Massachusetts Eye and Ear

Massachusetts Eye and Ear researchers have shown that mifepristone, a drug currently FDA-approved for chemical abortion, prevents the growth of vestibular schwannoma (also known as acoustic neuroma) cells. This sometimes-lethal intracranial tumor typically causes hearing loss and tinnitus. The findings, published online today in Scientific Reports, suggest that mifepristone is a promising drug candidate to be repositioned for the treatment of these tumors.
Mifepristone is an attractive candidate for repurposing, as it is relatively safe, well studied and carries minimal adverse effects. FDA-approved in 2000, mifepristone is most often used together with another medication, misoprostol, to end an early pregnancy. Adverse effects for mifepristone include mild fatigue, hot flashes, nausea and rash. Long-term use of mifepristone has been studied in clinical trials for other tumors, with minimal adverse effects reported after years of usage.

Based on the findings described in Scientific Reports, the study authors are cautiously optimistic about the therapeutic potential of for patients with vestibular schwannomas, either from NF2 or those arising sporadically. Dr. Stankovic hopes to begin a phase II clinical trial at Mass. Eye and Ear soon to determine efficacy of the drug for this indication.

"We are optimistic about the potential to repurpose this relatively safe drug for patients desperately in need of better solutions," she said.

Explore further: Toxic secretions from intracranial tumor damage the inner ear

More information: Jessica E. Sagers et al, Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma, Scientific Reports (2018). DOI: 10.1038/s41598-018-23609-7

Related Stories

Toxic secretions from intracranial tumor damage the inner ear

December 22, 2015
A new study at Massachusetts Eye and Ear showed that in some cases of vestibular schwannoma, a sometimes-lethal tumor often associated with neurofibromatosis 2 (NF2), secretions from the tumor contain toxic molecules that ...

Salicylates, a class of NSAIDs, stop vestibular schwannomas growth

February 5, 2015
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal ...

Aspirin intake may stop growth of vestibular schwannomas (acoustic neuromas)

January 24, 2014
Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted ...

Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2

February 5, 2018
Adding the targeted cancer therapy drug crizotinib to radiation therapy for tumors associated with the genetic disorder neurofibromatosis 2 (NF2) may reduce the hearing damage that can be exacerbated by radiotherapy. A Massachusetts ...

Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target

September 23, 2014
Researchers from the University of Toronto, directed by Drs. Gelareh Zadeh and Boris Krischek, investigated gene expression in normal vestibular nerves and vestibular schwannomas (VSs). Two important discoveries were made: ...

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Inflammatory bowel disease linked to prostate cancer

December 7, 2018
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.